Original Articles

The value of computed tomography perfusion for assessing the response of hepatocellular carcinoma to transarterial chemoembolization

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 2 July 2024
Accepted: 5 July 2024
Published: 13 September 2024
803
Views
444
Downloads
47
HTML

Authors

We determined the value of computed tomography perfusion (CTP) for assessing the response of hepatocellular carcinoma (HCC) to transarterial chemoembolization (TACE). 20 post-TACE HCC patients were re-evaluated with contrast-enhanced computed tomography and CTP. Patients with persistent arterial vascularization [non-response (NR)] or those with no arterial vascularization in the mass, but with signs of new nodules, underwent digital subtraction angiography (DSA), which was used to analyze image characteristics and CTP parameters of TACE-treated HCC. 27 post-TACE HCC masses (mean size 4.21 cm, range 2-6.5 cm) were observed in the 20 patients. The values yielded by CTP were 78.30±40.41 mL/min/100g and 33.67±38.74 mL/min/100g for hepatic arterial blood flow (HABF) and 51.40±17.80% and 25.60±26.53% for hepatic arterial fraction (HAF) in the NR group and complete response group, respectively. The NR group’s cutoff value of HABF was ≥55.95 mL/min/100g, with a sensitivity of 91.7% and specificity of 71.42%, and that of HAF was ≥32.55%, with a sensitivity of 92.3% and specificity of 83.33%. The CTP and DSA techniques showed high agreement in assessing the post-TACE responses of liver tumors (κ=0.872). The perfusion parameters HABF and HAF have high value for assessing post-TACE responses of HCC.

Downloads

Download data is not yet available.

Citations

Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v59-v64.
Yaghmai V, Besa C, Kim E, et al. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. Am J Roentgenol 2013;201:80-96.
Popovic P, Leban A, Kregar K, et al. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial chemoembolization of hepatocellular carcinoma. Radiol Oncol 2017;52:14-22.
Chen G, Ma DQ, He W, et al. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008;14:5738-43.
Kim SH, Kamaya A, Willmann JK. CT Perfusion of the Liver: Principles and Applications in Oncology. Radiology 2014;272:322-44.
Ippolito D, Capraro C, Casiraghi A, et al. Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol 2012;22:803-11.
Ippolito D, Fior D, Bonaffini PA, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 2014;83:1665-71.
Salem LN, Mohammed DM, Ziada DH, Elshafey MH. Dual input computed tomography perfusion in evaluating the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. Egypt J Radiol Nucl Med 2018;49:597-607.
Zhu Q, Zhang X, Li J, et al. Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy. Ann Transl Med 2015;3:285.
García-Figueiras R, Goh VJ, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool? Am J Roentgenol 2013;200:8-19.
Cheng HY, Shou Y, Wang X, et al. Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 2004;10:2753-5.
Petralia G, Summers P, Viotti S, et al. Quantification of Variability in breath-hold perfusion ct of hepatocellular carcinoma: a step toward clinical use. Radiology 2012;265:448-56.
Hayano K, Lee SH, Yoshida H, et al. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma. Acad Radiol 2014;21:654-60.
Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology 2014;272:322-44.
Su TH, He W, Jin L, et al. Early response of hepatocellular carcinoma to chemoembolization: volume computed tomography liver perfusion imaging as a short-term response predictor. J Comput Assist Tomogr 2017;41:315-20.
Enite AM, Rabee H. Multi-detector CT perfusion as a diagnostic imaging modality to evaluate local therapy of hepatocellular carcinoma. Egypt J Radiol Nucl Med 2016;47:687-92.
Osman MF, Shawali IH, Metwally LIA, et al. CT perfusion for response evaluation after interventional ablation of hepatocellular carcinoma: a prospective study. Egypt J Radiol Nucl Med 2021;52:281.
Nakakuma K, Tashiro S, Hiraoka T, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983;52:2193-200.

How to Cite



The value of computed tomography perfusion for assessing the response of hepatocellular carcinoma to transarterial chemoembolization. (2024). Italian Journal of Medicine, 18(3). https://doi.org/10.4081/itjm.2024.1768